Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”
04:58am, Thursday, 16'th Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Thursday that preclinical research on its experimental intranasal therapy showed potential to reduce brain...
Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson Congress
09:03am, Tuesday, 14'th Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
07:00am, Tuesday, 14'th Apr 2026
BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-
Ollie’s Bargain Outlet upgrade driven by outlet expansion, margin stability
08:02am, Thursday, 02'nd Apr 2026
Ollie's Bargain Outlet (NASDAQ:OLLI) has been upgraded to a ‘Buy’ rating by Jefferies analysts, who cited the company’s strong market position,...
Hochschild and Fresnillo slip as gold price knocked by Trump speech on Iran
05:10am, Thursday, 02'nd Apr 2026
Hochschild Mining PLC (LSE:HOC, OTCQX:HCHDF) and Fresnillo PLC (LSE:FRES) led a broad sell-off in FTSE 350 precious metals stocks on Thursday morning as...
Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum
01:10pm, Wednesday, 01'st Apr 2026
The recent data highlight nasal anti-CD3's potential in reversing cognitive decline associated with aging, which is a significant concern in neurodegenerative diseases.
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
09:20am, Wednesday, 01'st Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel approach to addressing neuroinflammation
RH stock tanks as fourth quarter results miss on the top and bottom lines
07:25am, Wednesday, 01'st Apr 2026
RH (NYSE:RH), the high-end home furnishings retailer, reported weaker-than-expected results for the fourth quarter of fiscal 2025, sending its shares down...
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
07:00am, Wednesday, 01'st Apr 2026
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
06:19am, Wednesday, 01'st Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel...
Dow Jones and Nasdaq futures flat as Nvidia and Salesforce earnings digested
02:59am, Thursday, 26'th Feb 2026
US stock futures were edging towards a flat start early on Thursday morning, as afterhours earnings from Nvidia and Salesforce continued to be digested....
Nasdaq extends gains as AI takes center stage with Nvidia, Salesforce earnings due
11:22am, Wednesday, 25'th Feb 2026
4:15pm: Big earnings due Tech led the way on Wednesday as investors positioned themselves ahead of a wave of major earnings reports. The Nasdaq jumped 1.3%...
Nasdaq makes strides as Nvidia and Salesforce prepare to report
10:47am, Wednesday, 25'th Feb 2026
3:45pm: Proactive news headlines Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data show its experimental intranasal therapy reduces brain...
Tiziana reports biomarker gains for nasal MS therapy in progressive disease
08:58am, Wednesday, 25'th Feb 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain inflammation and was associated with neuroprote
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-
